Bringing you the latest news, features and guidance advice from NICE NICE News
October 2011
Bringing you the latest news, features and guidance from NICE
New guidance
 
 

NICE gives green light to new clot-busting drug

 
 

NICE has recommended the use of ticagrelor (Brilique), in combination with low-dose aspirin for up to 12 months, for patients with acute coronary syndromes (ACS). Ticagrelor is an anti-platelet drug which works by reducing or preventing the formation of blood clots.

Read more  
 
 

Greater management of hyperglycaemia in patients with acute coronary syndromes needed

 
 

Patients with acute coronary syndromes (ACS) should have their blood glucose levels actively controlled if it is raised on admission to hospital, says NICE. Currently, hyperglycaemia is not being considered as a risk factor for ACS and frequently remains untreated.

 

Read more  
 
Also this month
 
 

Government plans to tackle obesity unveiled

NICE is to support local authorities in developing ways to tackle the rising tide of obesity in England, as the government plans to slash five billion calories off the nation's daily diet. On average adults are exceeding their daily calorie intake by 10 per cent, and people need to be more honest about what they eat and drink, according to the government's obesity strategy.

 

 
  Read more  
 
Also this month
 
 

Share your story on using NICE guidance for prestigious award

NICE is calling on organisations which have tried creative new ways to put NICE guidance into practice to enter the 2012 NICE Shared Learning Awards. Any organisation that uses NICE guidance is encouraged to apply. This includes NHS services, local authorities, charities, community groups or even private workplaces.

 

 

 

 
  Read more  
 
Into practice
 
 

New tools for hip fracture and rheumatoid arthritis

NICE has produced an online training module to help nurses with the management of hip fracture. The module covers the clinical and wider implications of having a hip fracture, and explains the importance of a co-ordinated multidisciplinary hip fracture programme and rehabilitation care.

 

An

 
  Read more  
 
New guidance
 
 

Have your say on draft guidance which recommends against the use of ipilmumab for the treatment of advanced malignant melanoma in people who have received prior chemotherapy. On the basis of evidence given so far, ipilimumab is not cost effective for use on the NHS.

 

Read more  
 
 

Comment on draft recommendations on identifying and managing tuberculosis among hard-to-reach groups such as substance misusers and some migrant populations. These groups often have difficulty recognising symptoms, accessing health services and taking medication.

Read more